"Antivir Ther"[ Journal] - Search Results

Year	Number of Results
1996	31
1997	28
1998	54
1999	53
2000	37
2001	41
2002	41
2003	81
2004	118
2005	127
2006	127
2007	148
2008	143
2009	134
2010	147
2011	199
2012	229
2013	175
2014	175
2015	152
2016	141
2017	92
2018	97
2019	73
2020	46
2021	18
2022	30
2023	24
2024	2

1

Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada.

Lepik KJ, Hunt OL, Bacani N, Wang L, Harris M, Toy J, McLinden T, Sereda P, Akagi LJ, Ready E, Montaner JS, Barrios R. Lepik KJ, et al. Antivir Ther. 2024 Feb;29(1):13596535241233128. doi: 10.1177/13596535241233128. Antivir Ther. 2024. PMID: 38375582 Free article.

2

Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.

Boussen I, Salmona M, Sicre De Fontbrune F, Xhaard A, De Castro N, Delaugerre C, Chaix ML, Molina JM. Boussen I, et al. Antivir Ther. 2024 Feb;29(1):13596535221097495. doi: 10.1177/13596535221097495. Antivir Ther. 2024. PMID: 38353416 Free article.

3

Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.

Margot N, Pennetzdorfer N, Naik V, Rhee M, Callebaut C. Margot N, et al. Antivir Ther. 2023 Dec;28(6):13596535231220754. doi: 10.1177/13596535231220754. Antivir Ther. 2023. PMID: 38085652 Free article.

4

Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report.

Zafar SJ, Gilliam BL, Schmalzle SA. Zafar SJ, et al. Antivir Ther. 2023 Dec;28(6):13596535231218875. doi: 10.1177/13596535231218875. Antivir Ther. 2023. PMID: 38048138 Free article. No abstract available.

5

RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway.

Shu D, Cheng L, Yuan K, Liu D, Wei H. Shu D, et al. Antivir Ther. 2023 Dec;28(6):13596535231219639. doi: 10.1177/13596535231219639. Antivir Ther. 2023. PMID: 38037795 Free article.

6

Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV.

Berko J, Mazonson P, Short D, Karris M, Ehui L, Gutner CA, Spinelli F, Zolopa A. Berko J, et al. Antivir Ther. 2023 Dec;28(6):13596535231216311. doi: 10.1177/13596535231216311. Antivir Ther. 2023. PMID: 38031911 Free article. Clinical Trial.

7

Subacute thyroiditis following COVID-19 vaccination: Case presentation.

Tomic AZ, Zafirovic SS, Gluvic ZM, Samardzic VS, Macvanin MT, Radunovic ML, Isenovic ER. Tomic AZ, et al. Antivir Ther. 2023 Oct;28(5):13596535231208831. doi: 10.1177/13596535231208831. Antivir Ther. 2023. PMID: 37861754 Free article.

8

Andrographolide inhibits infectious bronchitis virus-induced apoptosis, pyroptosis, and inflammation.

Shen J, Xu Q, Chen L, Chang X, Shen R, Zhao Z, Zhu L, Wu Y, Hou X. Shen J, et al. Antivir Ther. 2023 Oct;28(5):13596535231207499. doi: 10.1177/13596535231207499. Antivir Ther. 2023. PMID: 37846668 Free article.

9

HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective.

Carr A, Mackie NE, Paredes R, Ruxrungtham K. Carr A, et al. Antivir Ther. 2023 Oct;28(5):13596535231201162. doi: 10.1177/13596535231201162. Antivir Ther. 2023. PMID: 37749751 Free article. Review.

10

Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach.

Elkaeed EB, Alsfouk BA, Ibrahim TH, Arafa RK, Elkady H, Ibrahim IM, Eissa IH, Metwaly AM. Elkaeed EB, et al. Antivir Ther. 2023 Oct;28(5):13596535231199838. doi: 10.1177/13596535231199838. Antivir Ther. 2023. PMID: 37669909 Free article.

11

Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation.

Bassel M, Romanus D, Bo T, Sundberg AK, Okala S, Hirji I. Bassel M, et al. Antivir Ther. 2023 Oct;28(5):13596535231195431. doi: 10.1177/13596535231195431. Antivir Ther. 2023. PMID: 37657421 Free article.

12

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives.

Maqsood Q, Sumrin A, Iqbal M, Younas S, Hussain N, Mahnoor M, Wajid A. Maqsood Q, et al. Antivir Ther. 2023 Aug;28(4):13596535231189643. doi: 10.1177/13596535231189643. Antivir Ther. 2023. PMID: 37489502 Free article. Review.

13

Letter to the editor on use of antibodies from convalescent sera in the treatment of moderate and severe Covid-19 infection.

Nahhal SB, Awada B, Azzo JD, Wazzi-Mkahal R, Kanj S, Kanafani ZA. Nahhal SB, et al. Antivir Ther. 2023 Jun;28(3):13596535231186866. doi: 10.1177/13596535231186866. Antivir Ther. 2023. PMID: 37382216 Free article. No abstract available.

14

Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.

Zilwa N, Mpejane O, Mehboob G, Gill S, Kalinoski T. Zilwa N, et al. Antivir Ther. 2023 Jun;28(3):13596535231186727. doi: 10.1177/13596535231186727. Antivir Ther. 2023. PMID: 37368845 Free article.

15

Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV.

Armstrong I, Lacombe-Duncan A, Shokoohi M, Persad Y, Tseng A, Fung R, Underhill A, Côté P, Machouf N, Saucier A, Varriano B, Brundage M, Jones R, Weisdorf T, Goodhew J, MacLeod J, Loutfy M. Armstrong I, et al. Antivir Ther. 2023 Jun;28(3):13596535231182505. doi: 10.1177/13596535231182505. Antivir Ther. 2023. PMID: 37289725 Free article.

16

Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study.

Vingerhoets J, Van Dromme I, van Duijnhoven W, Anderson D, De Meyer S, Leopold L. Vingerhoets J, et al. Antivir Ther. 2023 Jun;28(3):13596535231174273. doi: 10.1177/13596535231174273. Antivir Ther. 2023. PMID: 37226302 Free article. Clinical Trial.

17

The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review.

Aberg JA, Mills A, Moreno S, Slater J, Prakash M, Clark A. Aberg JA, et al. Antivir Ther. 2023 Jun;28(3):13596535231174774. doi: 10.1177/13596535231174774. Antivir Ther. 2023. PMID: 37212748 Free article. Review.

18

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.

Pierson W, Tuefferd M, Herschke F, Slaets L, Crabbe M, Verstappen D, De Pelsmaeker S, Strickland I, Gane EJ, Schwabe C, Zhang Y, Meerts P, Vandenbossche J, Van Remoortere P, Verbrugge I, De Creus A. Pierson W, et al. Antivir Ther. 2023 Jun;28(3):13596535231172878. doi: 10.1177/13596535231172878. Antivir Ther. 2023. PMID: 37199270 Free article.

19

Lipid and glucose abnormalities and associated factors among children living with HIV in Asia.

Suwanlerk T, Rupasinghe D, Jantarabenjakul W, An VT, Ross JL, Kariminia A, Van Lam N, Kinikar A, Ounchanum P, Puthanakit T, Nik Yusoff NK, Lumbiganon P, Chokephaibulkit K, Viet DC, Sudjaritruk T, Moy FS, Wati DK, Mohamed TJ, Nallusamy R, Kumarasamy N, Khol V, Khanh TH, Kurniati N; TREAT Asia pediatric HIV Observational Database (TApHOD). Suwanlerk T, et al. Antivir Ther. 2023 Apr;28(2):13596535231170751. doi: 10.1177/13596535231170751. Antivir Ther. 2023. PMID: 37114944 Free PMC article.

20

Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts.

de Waal R, Rabie H, Technau KG, Eley B, Sipambo N, Cotton M, Boulle A, Wood R, Tanser F, Fatti G, Egger M, Davies MA; International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. de Waal R, et al. Antivir Ther. 2023 Feb;28(2):13596535231168480. doi: 10.1177/13596535231168480. Antivir Ther. 2023. PMID: 37038365 Free PMC article.

21

Rolle CP, Castano J, Nguyen V, Patel K, Hinestrosa F, DeJesus E. Rolle CP, et al. Antivir Ther. 2023 Feb;28(2):13596535231163703. doi: 10.1177/13596535231163703. Antivir Ther. 2023. PMID: 36896821 Free article.

22

Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation.

Kong F, Zeng XX. Kong F, et al. Antivir Ther. 2023 Feb;28(2):13596535231161488. doi: 10.1177/13596535231161488. Antivir Ther. 2023. PMID: 36861651 Free article.

23

Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review.

Peters E, Iwuji AC. Peters E, et al. Antivir Ther. 2023 Feb;28(1):13596535231159030. doi: 10.1177/13596535231159030. Antivir Ther. 2023. PMID: 36802921 Free article. Review.

24

Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ.

Rojas-Luna L, Posadas-Modragón A, Avila-Trejo AM, Alcántara-Farfán V, Rodríguez-Páez LI, Santiago-Cruz JA, Pastor-Alonso MO, Aguilar-Faisal JL. Rojas-Luna L, et al. Antivir Ther. 2023 Feb;28(1):13596535231155263. doi: 10.1177/13596535231155263. Antivir Ther. 2023. PMID: 36724136 Free article.

25

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.

Wu LS, Hu Y, Gane EJ, Slaets L, De Creus A, Ding Y, Niu J, Schwabe C, Goeyvaerts N, Xu Z, Huo D, Tuefferd M, Verbrugge I, Van Remoortere P, Schwertschlag U, Vandenbossche J. Wu LS, et al. Antivir Ther. 2023 Feb;28(1):13596535231151626. doi: 10.1177/13596535231151626. Antivir Ther. 2023. PMID: 36691849 Free article.

26

Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration.

Wieringa A, Ter Horst PG, Wagenvoort GH, Koch BC, Haringman JJ. Wieringa A, et al. Antivir Ther. 2023 Feb;28(1):13596535221150746. doi: 10.1177/13596535221150746. Antivir Ther. 2023. PMID: 36609161 Free article.

27

A favipiravir-induced angioedema and urticaria in a COVID-19 patient.

Ergur Ozturk F, Ozturk A, Ates H. Ergur Ozturk F, et al. Antivir Ther. 2022 Dec;27(6):13596535221146226. doi: 10.1177/13596535221146226. Antivir Ther. 2022. PMID: 36542553 Free article.

28

Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C.

Nkwocha CL, Carter PS, Blair S, Blackwell JM, Fasanmi EO. Nkwocha CL, et al. Antivir Ther. 2022 Dec;27(6):13596535221115253. doi: 10.1177/13596535221115253. Antivir Ther. 2022. PMID: 36495070 Free article.

29

Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients.

Boignard A, Augier C, Kheng M, Epaulard O, Germi R. Boignard A, et al. Antivir Ther. 2022 Dec;27(6):13596535221133619. doi: 10.1177/13596535221133619. Antivir Ther. 2022. PMID: 36398571 Free article.

30

EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.

Feld JJ, Lawitz E, Nguyen T, Lalezari J, Hassanein T, Martin P, Han SH, Dieterich D, Giard JM, De La Rosa G, Ahmad A, Luo E, Conery AL, Adda N. Feld JJ, et al. Antivir Ther. 2022 Dec;27(6):13596535221127848. doi: 10.1177/13596535221127848. Antivir Ther. 2022. PMID: 36382358 Free article.

31

Preface: Special Collection Commemorating John C. Martin.

Locarnini S, Richman D, Whitley R. Locarnini S, et al. Antivir Ther. 2022 Oct;27(5):13596535221123613. doi: 10.1177/13596535221123613. Antivir Ther. 2022. PMID: 36310438 Free article. No abstract available.

32

Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa.

Tyagi A, Tong Y, Rabideau DJ, Reynolds Z, De Oliveira T, Lessells R, Amanyire G, Orrell C, Asiimwe S, Chimukangara B, Giandhari J, Pillay S, Haberer JE, Siedner MJ; META Study Investigators. Tyagi A, et al. Antivir Ther. 2022 Oct;27(5):13596535221114822. doi: 10.1177/13596535221114822. Antivir Ther. 2022. PMID: 36263960 Free article.

33

A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection.

Krystal M, Chabria S, Austin D, Wolstenholme A, Wensel D, Lataillade M, Abberbock J, Baker M, Ackerman P. Krystal M, et al. Antivir Ther. 2022 Oct;27(5):13596535221131164. doi: 10.1177/13596535221131164. Antivir Ther. 2022. PMID: 36191080 Free article. Clinical Trial.

34

Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor.

Ara T, Endo T, Goto H, Kasahara K, Hasegawa Y, Yokoyama S, Shiratori S, Nakagawa M, Kuwahara K, Takakuwa E, Hashino S, Teshima T. Ara T, et al. Antivir Ther. 2022 Oct;27(5):13596535221126828. doi: 10.1177/13596535221126828. Antivir Ther. 2022. PMID: 36112852 Free article.

35

Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report.

van der Veer MA, Jacobs TG, Bukkems LH, Colbers AP, Burger DM, Scherpbier HJ, Bijleveld YA. van der Veer MA, et al. Antivir Ther. 2022 Aug;27(4):13596535221119932. doi: 10.1177/13596535221119932. Antivir Ther. 2022. PMID: 36062614 Free article.

36

The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.

Alvarez E, Campbell L, Tinago W, Garcia-Leon A, Walsh I, Brady JJ, Burling K, Noe S, Neuville MF, Jouret F, Jamshidian F, Graham H, Rhee M, Mallon PW, Post FA. Alvarez E, et al. Antivir Ther. 2022 Aug;27(4):13596535221094898. doi: 10.1177/13596535221094898. Antivir Ther. 2022. PMID: 36000318 Free article.

37

Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi.

Bello G, Kagoli M, Chipeta S, Auld A, Chang JC, DeVos JR, Kim E, Mkungudza J, Payne D, Eliya M, Nyirenda R, Jahn A, Mzumara T, Mvula B, Dadabhai S, Namakhoma I, Babaye Y, Giron A, Jordan MR, Bertagnolio S, O'Malley G, Wadonda-Kabondo N. Bello G, et al. Antivir Ther. 2022 Aug;27(4):13596535221121225. doi: 10.1177/13596535221121225. Antivir Ther. 2022. PMID: 35976773 Free PMC article.

38

Progress in the quality of care for newly diagnosed people with HIV in Spain (2004-2019).

Alejos B, Díez C, Galindo MJ, López JC, Moreno-García E, Estrada V, Poveda E, Omar M, Jarrín I, Berenguer J; For CoRIS. Alejos B, et al. Antivir Ther. 2022 Aug;27(4):13596535221112729. doi: 10.1177/13596535221112729. Antivir Ther. 2022. PMID: 35802475 Free article.

39

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.

European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc, Lyons A, Thompson L, Chappell E, Ene L, Galli L, Goetghebuer T, Jourdain G, Noguera-Julian A, Kahlert CR, Königs C, Kosalaraksa P, Lumbiganon P, Marczyńska M, Marques L, Navarro M, Naver L, Okhonskaia L, Prata F, Puthanakit T, Ramos JT, Samarina A, Thorne C, Voronin E, Turkova A, Giaquinto C, Judd A, Collins IJ. European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc, et al. Antivir Ther. 2022 Jun;27(3):13596535221092182. doi: 10.1177/13596535221092182. Antivir Ther. 2022. PMID: 36029009 Free PMC article.

40

Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV.

Wisch JK, Cooley SA, Yarasheski KE, Cade WT, Reeds DN, Nelson B, Alemu R, Burdo TH, Ances BM. Wisch JK, et al. Antivir Ther. 2022 Jun;27(3):13596535221109748. doi: 10.1177/13596535221109748. Antivir Ther. 2022. PMID: 35730471 Free article.

41

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.

Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. Gane E, et al. Antivir Ther. 2022 Jun;27(3):13596535221093856. doi: 10.1177/13596535221093856. Antivir Ther. 2022. PMID: 35695169 Free article. Clinical Trial.

42

Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.

Musengimana G, Tuyishime E, Kiromera A, Malamba SS, Mulindabigwi A, Habimana MR, Baribwira C, Ribakare M, Habimana SD, DeVos J, Mwesigwa RCN, Kayirangwa E, Semuhore JM, Rwibasira GN, Suthar AB, Remera E. Musengimana G, et al. Antivir Ther. 2022 Jun;27(3):13596535221102690. doi: 10.1177/13596535221102690. Antivir Ther. 2022. PMID: 35593031 Free PMC article.

43

Adefovir for lamivudine-resistant hepatitis B.

Roediger R, Smyth EK, Dieterich D. Roediger R, et al. Antivir Ther. 2022 Apr;27(2):13596535211067605. doi: 10.1177/13596535211067605. Antivir Ther. 2022. PMID: 35499182 Free article. Review.

44

Discovery and development of oseltamivir at Gilead Sciences.

Schmitz U, Swaminathan S. Schmitz U, et al. Antivir Ther. 2022 Apr;27(2):13596535211067598. doi: 10.1177/13596535211067598. Antivir Ther. 2022. PMID: 35499178 Free article.

45

Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis.

Razavi H. Razavi H. Antivir Ther. 2022 Apr;27(2):13596535221083179. doi: 10.1177/13596535221083179. Antivir Ther. 2022. PMID: 35499176 Free article.

46

Tenofovir alafenamide fumarate.

Lee WA, Cheng AK. Lee WA, et al. Antivir Ther. 2022 Apr;27(2):13596535211067600. doi: 10.1177/13596535211067600. Antivir Ther. 2022. PMID: 35499175 Free article.

47

Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.

Abdool Karim SS, Baxter C, Abdool Karim Q. Abdool Karim SS, et al. Antivir Ther. 2022 Apr;27(2):13596535211067589. doi: 10.1177/13596535211067589. Antivir Ther. 2022. PMID: 35499171 Free article.

48

The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B.

Pan CQ. Pan CQ. Antivir Ther. 2022 Apr;27(2):13596535221076640. doi: 10.1177/13596535221076640. Antivir Ther. 2022. PMID: 35499165 Free article.

49

Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19.

Cihlar T, Mackman RL. Cihlar T, et al. Antivir Ther. 2022 Apr;27(2):13596535221082773. doi: 10.1177/13596535221082773. Antivir Ther. 2022. PMID: 35499114 Free article.

50

Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection.

Whitley RJ. Whitley RJ. Antivir Ther. 2022 Apr;27(2):13596535211060968. doi: 10.1177/13596535211060968. Antivir Ther. 2022. PMID: 35499094 Free article.

51

The transformation of HIV therapy: One pill once a day.

Choudhary MC, Mellors JW. Choudhary MC, et al. Antivir Ther. 2022 Apr;27(2):13596535211062396. doi: 10.1177/13596535211062396. Antivir Ther. 2022. PMID: 35492017 Free article.

52

Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case.

Alton G, Samuel C, Reddi A. Alton G, et al. Antivir Ther. 2022 Apr;27(2):13596535211068617. doi: 10.1177/13596535211068617. Antivir Ther. 2022. PMID: 35491613 Free article.

53

The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.

Schinazi RF, Patel D, Ehteshami M. Schinazi RF, et al. Antivir Ther. 2022 Apr;27(2):13596535211067599. doi: 10.1177/13596535211067599. Antivir Ther. 2022. PMID: 35491570 Free article. Review.

54

The making of the one pill-Developing single tablet regimens for HIV and for HCV.

Yang T, Oliyai R, Kent KM. Yang T, et al. Antivir Ther. 2022 Apr;27(2):13596535211067606. doi: 10.1177/13596535211067606. Antivir Ther. 2022. PMID: 35491563 Free article.

55

Case study of hepatitis C virus control in Egypt: impact of access program.

Waked I. Waked I. Antivir Ther. 2022 Apr;27(2):13596535211067592. doi: 10.1177/13596535211067592. Antivir Ther. 2022. PMID: 35491550 Free article.

56

The curing regimens of HCV: A SWOT analysis.

Cornberg M, Manns MP. Cornberg M, et al. Antivir Ther. 2022 Feb-Apr;27(1-2):13596535211072672. doi: 10.1177/13596535211072672. Antivir Ther. 2022. PMID: 35491553 Free article.

57

Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.

Molina JM, Ene L, Cahn P, Fätkenheuer G, Van Wijngaerden E, Lombaard J, Zakharova N, Van Eygen V, Vanveggel S, Van Solingen-Ristea R. Molina JM, et al. Antivir Ther. 2021 Nov;26(6-8):95-105. doi: 10.1177/13596535211062388. Epub 2021 Nov 26. Antivir Ther. 2021. PMID: 35485339 Clinical Trial.

58

HBV co-infection is associated with persistently elevated liver stiffness measurement in HIV-positive adults: A 6-year single-centre cohort study in Nigeria.

Rivera AS, Machenry S, Okpokwu J, Olatunde B, Ugoagwu P, Auwal M, Sule H, Agaba P, Agbaji OO, Thio CL, Murphy RL, Hawkins C. Rivera AS, et al. Antivir Ther. 2021 Nov;26(6-8):106-116. doi: 10.1177/13596535211058262. Epub 2021 Nov 22. Antivir Ther. 2021. PMID: 35485338

59

Impact of new cyclooxygenase 2 inhibitors on human cytomegalovirus replication in vitro.

Andouard D, Gueye R, Hantz S, Fagnère C, Liagre B, Bernardaud L, Pouget C, Duroux JL, Alain S. Andouard D, et al. Antivir Ther. 2021 Nov;26(6-8):117-125. doi: 10.1177/13596535211064078. Epub 2021 Nov 29. Antivir Ther. 2021. PMID: 35485337

60

A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients.

Fang YQ, Xu XY, Hou FQ, Jia W. Fang YQ, et al. Antivir Ther. 2021 Nov;26(6-8):126-133. doi: 10.1177/13596535211059895. Epub 2021 Nov 16. Antivir Ther. 2021. PMID: 35485336

61

Topical cidofovir for benign human papillomavirus-associated skin lesions.

Napolitano L, Schroedl L, Kerman A, Shea CR. Napolitano L, et al. Antivir Ther. 2021 Nov;26(6-8):141-146. doi: 10.1177/13596535211059889. Epub 2021 Nov 2. Antivir Ther. 2021. PMID: 35485335

62

Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.

Pressiat C, Dainguy E, Tréluyer JM, Yonaba C, Urien S, Eboua F, Foissac F, Dahourou DL, Bouazza N, Malateste K, Desmonde S, Pruvost A, Leroy V, Hirt D, Study Group TMA. Pressiat C, et al. Antivir Ther. 2021 Nov;26(6-8):134-140. doi: 10.1177/13596535211058267. Epub 2021 Nov 16. Antivir Ther. 2021. PMID: 35485334

63

Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.

Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Maggiolo F, et al. Antivir Ther. 2021 May;26(3-5):51-57. doi: 10.1177/13596535211042226. Epub 2021 Oct 27. Antivir Ther. 2021. PMID: 35485333 Clinical Trial.

64

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults.

Gane E, Pastagia M, Schwertschlag U, De Creus A, Schwabe C, Vandenbossche J, Slaets L, Fevery B, Smyej I, Wu LS, Li R, Siddiqui S, Oey A, Musto C, Van Remoortere P. Gane E, et al. Antivir Ther. 2021 May;26(3-5):58-68. doi: 10.1177/13596535211056581. Epub 2021 Oct 27. Antivir Ther. 2021. PMID: 35485332

65

Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.

Scheibe K, Urbańska A, Jakubowski P, Hlebowicz M, Bociąga-Jasik M, Raczyńska A, Szymczak A, Szetela B, Łojewski W, Parczewski M. Scheibe K, et al. Antivir Ther. 2021 May;26(3-5):69-78. doi: 10.1177/13596535211043044. Epub 2021 Oct 20. Antivir Ther. 2021. PMID: 35485331

66

Evaluation of doravirine-based regimen population target in a large Italian clinical center.

Farinacci D, Ciccullo A, Lombardi F, Moschese D, D'Angelillo A, Iannone V, Lamanna F, Passerotto RA, Giambenedetto SD. Farinacci D, et al. Antivir Ther. 2021 May;26(3-5):79-83. doi: 10.1177/13596535211056556. Epub 2021 Oct 25. Antivir Ther. 2021. PMID: 35485330

67

Oseltamivir and acute hepatitis, reality association or coincidence?

Mastroianni A, Vangeli V, Greco S, Urso F, Greco F, Chidichimo L, Mauro MV. Mastroianni A, et al. Antivir Ther. 2021 May;26(3-5):87-92. doi: 10.1177/13596535211041494. Epub 2021 Sep 17. Antivir Ther. 2021. PMID: 35485329 Review.

68

Real-life findings on the impact of the COVID-19 pandemic on HIV care.

Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Ciccullo A, et al. Antivir Ther. 2021 May;26(3-5):84-86. doi: 10.1177/13596535211052215. Epub 2021 Oct 19. Antivir Ther. 2021. PMID: 35485328 No abstract available.

69

Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy.

Zhang H, Chen F, Giang E, Bao F, Lauer GM, Marsh C, Law M, Pockros PJ. Zhang H, et al. Antivir Ther. 2021 Jan-Feb;26(1-2):3-8. doi: 10.1177/13596535211042205. Epub 2021 Sep 26. Antivir Ther. 2021. PMID: 35485347 Free PMC article.

70

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.

Kakuda TN, Yogaratnam JZ, Westland C, Gane EJ, Schwabe C, Vuong J, Patel M, Snoeys J, Talloen W, Lenz O, Fry J, Chanda S, van Remoortere P. Kakuda TN, et al. Antivir Ther. 2021 Jan-Feb;26(1-2):13-24. doi: 10.1177/13596535211044331. Epub 2021 Sep 23. Antivir Ther. 2021. PMID: 35485346 Clinical Trial.

71

Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.

Lee JE, Lee SO, Heo J, Kim DW, Park MR, Son H, Kim D, Kim KH, Lee S, Lee SH. Lee JE, et al. Antivir Ther. 2021 Jan-Feb;26(1-2):34-42. doi: 10.1177/13596535211039394. Epub 2021 Sep 2. Antivir Ther. 2021. PMID: 35485345

72

Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4⁺ cell counts.

Kouamé GM, Gabillard D, Moh R, Badje A, Ntakpé JB, Emième A, Maylin S, Toni TD, Ménan H, Zoulim F, Danel C, Anglaret X, Eholié S, Lacombe K, Boyd A. Kouamé GM, et al. Antivir Ther. 2021 Jan-Feb;26(1-2):25-33. doi: 10.1177/13596535211039589. Epub 2021 Sep 4. Antivir Ther. 2021. PMID: 35485344 Clinical Trial.

73

Antiviral effect of Artemisia aucheri aqueous extract on UL46 and US6 genes of HSV-1.

Zamanian M, Sharifi Z, Noormohammadi Z, Akbarzadeh T, Bineshian F. Zamanian M, et al. Antivir Ther. 2021 Jan-Feb;26(1-2):43-48. doi: 10.1177/13596535211039907. Epub 2021 Sep 2. Antivir Ther. 2021. PMID: 35485343

74

An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis.

Ugarte A, De la Mora L, Martínez-Rebollar M, Mallolas J, Laguno M. Ugarte A, et al. Antivir Ther. 2021 Jan-Feb;26(1-2):9-12. doi: 10.1177/13596535211045832. Epub 2021 Sep 20. Antivir Ther. 2021. PMID: 35485342 No abstract available.

75

Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy.

Lipinski J, Margevicius S, Schluchter MD, Wilson DL, McComsey GA, Longenecker CT. Lipinski J, et al. Antivir Ther. 2020;25(8):419-427. doi: 10.3851/IMP3389. Antivir Ther. 2020. PMID: 33901017 Clinical Trial.

76

Treatment modification after second-line failure among people living with HIV in the Asia-Pacific.

Jiamsakul A, Azwa I, Zhang F, Yunihastuti E, Ditangco R, Kumarasamy N, Ng OT, Chan YJ, Ly PS, Choi JY, Lee MP, Pujari S, Kiertiburanakul S, Chaiwarith R, Merati TP, Sangle S, Khusuwan S, Sim BL, Avihingsanon A, Duy C, Tanuma J, Ross J, Law M, Asia-Pacific TAHODOI. Jiamsakul A, et al. Antivir Ther. 2020;25(7):377-387. doi: 10.3851/IMP3388. Antivir Ther. 2020. PMID: 33843656 Free PMC article.

77

Cytomegalovirus infection associated with severe intraocular inflammation in an HIV patient: a case report.

Lezcano Carduz VP, Alba NA, Almagro EG, Pernaute OS. Lezcano Carduz VP, et al. Antivir Ther. 2020;25(6):341-344. doi: 10.3851/IMP3381. Antivir Ther. 2020. PMID: 33824246

78

Effect of vitamin D₃ and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV.

Yin MT, Bucovsky M, Williams J, Brunjes D, RoyChoudhury A, Colon I, Ferris DC, Olender S, Schulze PC, Sharma A, Zeana C, Zingman B, Shane E. Yin MT, et al. Antivir Ther. 2020;25(8):411-418. doi: 10.3851/IMP3386. Antivir Ther. 2020. PMID: 33705355 Free PMC article. Clinical Trial.

79

Antiviral activity of 1,4-disubstituted-1,2,3-triazoles against HSV-1 in vitro.

Viegas DJ, da Silva VD, Buarque CD, Bloom DC, Abreu PA. Viegas DJ, et al. Antivir Ther. 2020;25(8):399-410. doi: 10.3851/IMP3387. Antivir Ther. 2020. PMID: 33705354

80

The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.

Dorward J, Gbinigie O, Cai T, Roberts NW, Garrett N, Hayward G, Butler CC. Dorward J, et al. Antivir Ther. 2020;25(7):365-376. doi: 10.3851/IMP3385. Antivir Ther. 2020. PMID: 33704086 Review.

81

Antiviral activity of different extracts of standardized propolis preparations against HSV.

Demir S, Atayoglu AT, Galeotti F, Garzarella EU, Zaccaria V, Volpi N, Karagoz A, Sahin F. Demir S, et al. Antivir Ther. 2020;25(7):353-363. doi: 10.3851/IMP3383. Antivir Ther. 2020. PMID: 33620334

82

How can the latent cytomegalovirus cause an increase in all-cause mortality? An answer based on the microcompetition model.

Polansky H. Polansky H. Antivir Ther. 2020;25(7):349-351. doi: 10.3851/IMP3384. Antivir Ther. 2020. PMID: 33616550

83

COVID-19 and hepatitis B infection.

Alqahtani SA, Buti M. Alqahtani SA, et al. Antivir Ther. 2020;25(8):389-397. doi: 10.3851/IMP3382. Antivir Ther. 2020. PMID: 33616549

84

Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.

Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciaro R, Ghisetti V, Fava C, Bonora S, Di Perri G, Calcagno A; e-COVID Study Group. Trunfio M, et al. Antivir Ther. 2020;25(6):327-333. doi: 10.3851/IMP3377. Antivir Ther. 2020. PMID: 33506810

85

Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.

Alejos B, Suárez-García I, Bernardino JI, Blanco JR, Peñaranda M, Bautista A, Gutiérrez F, Jarrín I, Hernando V; CORIS cohort†. Alejos B, et al. Antivir Ther. 2020;25(6):335-340. doi: 10.3851/IMP3380. Antivir Ther. 2020. PMID: 33470219

86

An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia.

Bijker R, Kumarasamy N, Kiertiburanakul S, Pujari S, Ng OT, Sun LP, Merati TP, Van Nguyen K, Lee MP, Cuong DD, Chan YJ, Choi JY, Ross J, Law M; IeDEA Asia-Pacific. Bijker R, et al. Antivir Ther. 2020;25(5):275-285. doi: 10.3851/IMP3379. Antivir Ther. 2020. PMID: 33464222 Free PMC article.

87

Weight gain during pregnancy in women with HIV receiving different antiretroviral regimens.

Floridia M, Masuelli G, Tassis B, Franceschetti L, Savasi VM, Spinillo A, Tamburrini E, Guaraldi G, Dalzero S, Sansone M, Chiodo A, Antoni AMD, Pinnetti C, Liuzzi G, Ravizza M; Italian Group on Surveillance of Antiretroviral Treatment in Pregnancy. Floridia M, et al. Antivir Ther. 2020;25(6):315-325. doi: 10.3851/IMP3376. Antivir Ther. 2020. PMID: 33459635

88

Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?

Post FA, Hamzah L. Post FA, et al. Antivir Ther. 2020;25(5):241-243. doi: 10.3851/IMP3378. Antivir Ther. 2020. PMID: 33459634

89

Viral suppression is comparable with 0.5 mg and 1.0 mg daily doses of entecavir in treatment-naive HBV-related decompensated cirrhosis.

Goel A, Rungta S, Verma P, Verma A, Verma AN, Rai P, Aggarwal R. Goel A, et al. Antivir Ther. 2020;25(5):267-273. doi: 10.3851/IMP3375. Antivir Ther. 2020. PMID: 33404519

90

Assessing bias introduced in estimated glomerular filtration rate by the inhibition of creatinine tubular secretion from common antiretrovirals.

Brunet L, Wyatt C, Hsu R, Mounzer K, Fusco J, Fusco G. Brunet L, et al. Antivir Ther. 2020;25(5):287-292. doi: 10.3851/IMP3373. Antivir Ther. 2020. PMID: 33211670

91

Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

Jia J, Shang J, Tang H, Jiang J, Ning Q, Dou X, Zhang S, Zhang M, Han T, Tan D, Zhou X, Chen G, Sheng J, Su Z, Chen H, Dai E, Ye Y, Guo Y, Shen Y, Yuan J, Wei Z, Zhu S; EVOLVE Study Group. Jia J, et al. Antivir Ther. 2020;25(6):293-304. doi: 10.3851/IMP3372. Antivir Ther. 2020. PMID: 33090970

92

Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study.

Pillay T, Cornell M, Fox MP, Euvrard J, Fatti G, Technau KG, Sipambo N, Prozesky H, Eley B, Tanser F, Johnson LF. Pillay T, et al. Antivir Ther. 2020;25(5):257-266. doi: 10.3851/IMP3371. Antivir Ther. 2020. PMID: 32960187 Free PMC article.

93

Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.

Ren S, Wei F, Jin Y, Lu J, He Z, Ma L, Zheng Y, Wang J, Chen X. Ren S, et al. Antivir Ther. 2020;25(5):245-255. doi: 10.3851/IMP3369. Antivir Ther. 2020. PMID: 32936785

94

Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.

Chayanupatkul M, Chittmittraprap S, Pratedrat P, Chuaypen N, Avihingsanon A, Tangkijvanich P. Chayanupatkul M, et al. Antivir Ther. 2020;25(6):305-314. doi: 10.3851/IMP3370. Antivir Ther. 2020. PMID: 32910788

95

Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B.

Beudeker BJ, Groothuismink ZM, de Man RA, Janssen H, van der Eijk AA, Boonstra A, Sonneveld MJ. Beudeker BJ, et al. Antivir Ther. 2020;25(4):217-222. doi: 10.3851/IMP3367. Antivir Ther. 2020. PMID: 32744512 Clinical Trial.

96

Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system.

Jarvis MA, Hansen FA, Rosenke K, Haddock E, Rollinson C, Rule S, Sewell G, Hughes A, Feldmann H. Jarvis MA, et al. Antivir Ther. 2020;25(4):223-231. doi: 10.3851/IMP3368. Antivir Ther. 2020. PMID: 32744511

97

Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.

Reyes M, Lutz JD, Lau AH, Gaggar A, Grant EP, Joshi A, Mackman RL, Ling J, Tan SK, Ayithan N, Daffis S, Woo J, Wu P, Lam T, Fletcher SP, Kottilil S, Poonia B, Gane EJ, Mathias A, German P. Reyes M, et al. Antivir Ther. 2020;25(3):171-180. doi: 10.3851/IMP3363. Antivir Ther. 2020. PMID: 32667286 Clinical Trial.

98

Dynamics of HBV surface antigen related end points in chronic hepatitis B infection: a systematic review and meta-analysis.

Chen Y, Li JJ, Chen R, Li G, Ji J. Chen Y, et al. Antivir Ther. 2020;25(4):203-215. doi: 10.3851/IMP3366. Antivir Ther. 2020. PMID: 32609658

99

The effects of nucleoside/nucleotide analogues on host immune cells: the baseline for future immune therapy for HBV?

Boeijen LL, Spaan M, Boonstra A. Boeijen LL, et al. Antivir Ther. 2020;25(4):181-191. doi: 10.3851/IMP3364. Antivir Ther. 2020. PMID: 32589166 Review.

100

SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.

Smolders EJ, Te Brake LH, Burger DM. Smolders EJ, et al. Antivir Ther. 2020;25(7):345-347. doi: 10.3851/IMP3365. Antivir Ther. 2020. PMID: 32589165

101

Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes.

Foca A, Dhillon A, Lahlali T, Lucifora J, Salvetti A, Rivoire M, Lee A, Durantel D. Foca A, et al. Antivir Ther. 2020;25(3):151-162. doi: 10.3851/IMP3361. Antivir Ther. 2020. PMID: 32496211 Free article.

102

Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.

Xie X, Jiang Y, Zeng Y, Liu H. Xie X, et al. Antivir Ther. 2020;25(4):233-239. doi: 10.3851/IMP3362. Antivir Ther. 2020. PMID: 32496210

103

Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China.

Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Zhang Q, et al. Antivir Ther. 2020;25(3):143-149. doi: 10.3851/IMP3360. Antivir Ther. 2020. PMID: 32478676

104

Activation of HIV-specific CD8⁺ T-cells from HIV+ donors by vesatolimod.

Ram RR, Duatschek P, Margot N, Abram M, Geleziunas R, Hesselgesser J, Callebaut C. Ram RR, et al. Antivir Ther. 2020;25(3):163-169. doi: 10.3851/IMP3359. Antivir Ther. 2020. PMID: 32420906

105

Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

Bijker R, Kiertiburanakul S, Kumarasamy N, Pujari S, Sun LP, Ng OT, Lee MP, Choi JY, Nguyen KV, Chan YJ, Merati TP, Cuong DD, Ross J, Jiamsakul A; IeDEA Asia-Pacific. Bijker R, et al. Antivir Ther. 2020;25(3):131-142. doi: 10.3851/IMP3358. Antivir Ther. 2020. PMID: 32369040 Free PMC article.

106

Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.

Al-Nahari MM, Abbassi MM, Ebeid FS, Hassany M, El-Sayed MH, Farid SF. Al-Nahari MM, et al. Antivir Ther. 2020;25(2):101-110. doi: 10.3851/IMP3357. Antivir Ther. 2020. PMID: 32367815

107

HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era.

Toka B, Koksal AS, İskender G, Çakmak E, Üsküdar O, Sezikli M, Şirin G, Yildirim AE, Fidan S, Acar Ş, Eminler AT, Uslan MI, Hülagü S. Toka B, et al. Antivir Ther. 2020;25(3):121-129. doi: 10.3851/IMP3356. Antivir Ther. 2020. PMID: 32364531

108

The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.

Blackman AL, Heil EL, Devanathan AS, Pandit NS. Blackman AL, et al. Antivir Ther. 2020;25(2):115-119. doi: 10.3851/IMP3355. Antivir Ther. 2020. PMID: 32341207 Free PMC article.

109

CD4⁺:CD8⁺ T-cell ratio changes in people with HIV receiving antiretroviral treatment.

Vivancos-Gallego MJ, Okhai H, Perez-Elías MJ, Gomez-Ayerbe C, Moreno-Zamora A, Casado JL, Quereda C, Sanz JM, Sanchez-Conde M, Serrano-Villar S, Del Campo S, Dronda F, Galan JC, Sabin CA, Moreno S. Vivancos-Gallego MJ, et al. Antivir Ther. 2020;25(2):91-100. doi: 10.3851/IMP3354. Antivir Ther. 2020. PMID: 32338638

110

DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study.

Alessio L, Onorato L, Sangiovanni V, Borrelli F, Manzillo E, Esposito V, Simeone F, Martini S, Capoluongo N, Leone S, Di Filippo G, D'Abbraccio M, Aprea L, Megna AS, Milano E, Rizzo V, Saracino A, Coppola N. Alessio L, et al. Antivir Ther. 2020;25(4):193-201. doi: 10.3851/IMP3353. Antivir Ther. 2020. PMID: 32314978

111

Multidrug-resistant cytomegalovirus infection in a patient with granulomatosis with polyangiitis during immunosuppressive treatment.

Piccirilli G, Chiereghin A, Maritati M, Turello G, Felici S, La Corte R, Gabrielli L, Contini C, Lazzarotto T. Piccirilli G, et al. Antivir Ther. 2020;25(2):111-114. doi: 10.3851/IMP3352. Antivir Ther. 2020. PMID: 32297594

112

Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort.

Quaranta MG, Rosato S, Ferrigno L, Amoruso DC, Monti M, Di Stefano P, Filomia R, Biliotti E, Migliorino G, Russo FP, Degasperi E, Chemello L, Brancaccio G, Blanc P, Cannizzaro M, Barbaro F, Morsica G, Licata A, Kondili LA; PITER collaborating group. Quaranta MG, et al. Antivir Ther. 2020;25(2):73-81. doi: 10.3851/IMP3350. Antivir Ther. 2020. PMID: 32242526

113

Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.

Hoffmann C, Schewe K, Fenske S, Buhk T, Sabranski M, Adam A, Hansen S, Stellbrink HJ. Hoffmann C, et al. Antivir Ther. 2020;25(2):83-90. doi: 10.3851/IMP3351. Antivir Ther. 2020. PMID: 32235038

114

Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018.

Kusejko K, Marzel A, Nguyen H, Chaudron SE, Bachmann N, Weber R, Bruggmann P, Roth JA, Bernasconi E, Calmy A, Cavassini M, Bregenzer A, Böni J, Yerly S, Klimkait T, Perreau M, Walti LN, Günthard HF, Kouyos RD; Swiss HIV Cohort Study. Kusejko K, et al. Antivir Ther. 2020;25(1):43-54. doi: 10.3851/IMP3347. Antivir Ther. 2020. PMID: 32235037

115

Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.

Arenas-Pinto A, Stöhr W, Khoo S, Clarke A, Beeching N, Warwick Z, Lee V, Else L, Wiggins R, Ferns B, Nastouli E, Dunn D, Lacey CJ, Paton NI; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Genital Secretion sub-study Team†. Arenas-Pinto A, et al. Antivir Ther. 2020;25(1):55-59. doi: 10.3851/IMP3340. Antivir Ther. 2020. PMID: 32202510

116

Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA.

Bavaro DF, Di Carlo D, Rossetti B, Bruzzone B, Vicenti I, Pontali E, Zoncada A, Lombardi F, Di Giambenedetto S, Borghi V, Pecorari M, Milini P, Meraviglia P, Monno L, Saracino A. Bavaro DF, et al. Antivir Ther. 2020;25(2):61-71. doi: 10.3851/IMP3349. Antivir Ther. 2020. PMID: 32118584

117

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.

Baranek B, Wang S, Cheung AM, Mishra S, Tan DH. Baranek B, et al. Antivir Ther. 2020;25(1):21-32. doi: 10.3851/IMP3346. Antivir Ther. 2020. PMID: 32077867

118

Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women.

Deng H, Liang S, Xu M, Zhuo L, Gao H, Chen K, Shi Y, Li H, Jiao Q, Lin L, Lei Y, Liu H. Deng H, et al. Antivir Ther. 2020;25(1):33-41. doi: 10.3851/IMP3345. Antivir Ther. 2020. PMID: 32049069

119

Antiviral activity of 4-oxoquinoline-3-carboxamide derivatives against bovine herpesvirus type 5.

Pinto AMV, Leite JPG, Marinho RS, Forezi LDS, Batalha PN, Boechat FDC, Cunha AC, Silva DO, Gama IL, Faro LV, de Souza MC, Paixão ICP. Pinto AMV, et al. Antivir Ther. 2020;25(1):13-20. doi: 10.3851/IMP3329. Antivir Ther. 2020. PMID: 31538962

120

Perillyl alcohol and perillic acid exert efficient action upon HSV-1 maturation and release of infective virus.

Mello CP, Quirico-Santos T, Amorim LF, Silva VG, Fragel LM, Bloom DC, Paixão IP. Mello CP, et al. Antivir Ther. 2020;25(1):1-11. doi: 10.3851/IMP3315. Antivir Ther. 2020. PMID: 31099756

121

Transmitted, pre-treatment and acquired antiretroviral drug resistance among men who have sex with men and transgender women living with HIV in Nigeria.

Crowell TA, Kijak GH, Sanders-Buell E, O'Sullivan AM, Kokogho A, Parker ZF, Lawlor J, Polyak CS, Adebajo S, Nowak RG, Baral SD, Robb ML, Charurat ME, Ake JA, Ndembi N, Tovanabutra S; TRUST/RV368 Study Group. Crowell TA, et al. Antivir Ther. 2019;24(8):595-601. doi: 10.3851/IMP3342. Antivir Ther. 2019. PMID: 32125280 Free PMC article.

122

In vitro anti-influenza activity of in silico repurposed candidate drug cycrimine.

Matejin S, Bukreyeva N, Radosevic D, Sencanski M, Mantlo E, Veljkovic V, Glisic S, Paessler S. Matejin S, et al. Antivir Ther. 2019;24(8):589-593. doi: 10.3851/IMP3348. Antivir Ther. 2019. PMID: 32108589

123

Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.

Abed Y, Schibler M, Checkmahomed L, Carbonneau J, Venable MC, Fage C, Giannotti F, Goncalves AR, Kaiser L, Boivin G. Abed Y, et al. Antivir Ther. 2019;24(8):581-587. doi: 10.3851/IMP3344. Antivir Ther. 2019. PMID: 32031540

124

Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.

Majeed SR, West S, Ling KH, Das M, Kearney BP. Majeed SR, et al. Antivir Ther. 2019;24(8):557-566. doi: 10.3851/IMP3343. Antivir Ther. 2019. PMID: 31933482 Clinical Trial.

125

Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review.

Bierhoff M, Smolders EJ, Tarning J, Burger DM, Spijker R, Rijken MJ, Angkurawaranon C, McGready R, White NJ, Nosten F, van Vugt M. Bierhoff M, et al. Antivir Ther. 2019;24(7):529-540. doi: 10.3851/IMP3341. Antivir Ther. 2019. PMID: 31868655

126

Elevated risk of viral rebound on ART in migrants living in France: role of socioeconomic factors.

Abgrall S, Raho-Moussa M, Seng R, Ghislain M, Matheron S, Pialoux G, Goujard C, Meyer L; ANRS CO9-COPANA study group†. Abgrall S, et al. Antivir Ther. 2019;24(7):541-552. doi: 10.3851/IMP3339. Antivir Ther. 2019. PMID: 31868654

127

Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.

Abreu RM, Bassit LC, Tao S, Jiang Y, Ferreira AS, Hori PC, Ganova-Raeva LM, Khudyakov Y, Schinazi RF, Carrilho FJ, Ono SK. Abreu RM, et al. Antivir Ther. 2019;24(8):567-579. doi: 10.3851/IMP3338. Antivir Ther. 2019. PMID: 31799942 Free PMC article.

128

Low vitamin D is associated with coronary atherosclerosis in women with HIV.

Cheru LT, Saylor CF, Fitch KV, Looby SE, Lu M, Hoffmann U, Stanley TL, Lo J. Cheru LT, et al. Antivir Ther. 2019;24(7):505-512. doi: 10.3851/IMP3336. Antivir Ther. 2019. PMID: 31742564 Free PMC article.

129

21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.

[No authors listed] [No authors listed] Antivir Ther. 2019;24(Suppl 1):A1-A112. Antivir Ther. 2019. PMID: 31697264 No abstract available.

130

Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors.

Chastain DB, Veve MP, Wagner JL. Chastain DB, et al. Antivir Ther. 2019;24(6):459-465. doi: 10.3851/IMP3335. Antivir Ther. 2019. PMID: 31570667

131

High frequency of drug resistance mutations in the HBV genome in ART-experienced HIV-coinfected patients in southwestern Nigeria.

Akanbi OA, Harms D, Wang B, Osundare FA, Adesina O, Oluremi AS, Omoruyi EC, Kappert K, Opaleye OO, Bock CT. Akanbi OA, et al. Antivir Ther. 2019;24(7):521-528. doi: 10.3851/IMP3333. Antivir Ther. 2019. PMID: 31566576

132

Real-world clinical outcomes among individuals with chronic HCV infection in China: CCgenos study.

Rao H, Xie Q, Shang J, Gao Z, Chen H, Sun Y, Jiang J, Niu J, Zhang L, Wang L, Zhao L, Li J, Yang R, Zhu S, Li R, Wei L. Rao H, et al. Antivir Ther. 2019;24(7):473-483. doi: 10.3851/IMP3334. Antivir Ther. 2019. PMID: 31566575

133

Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.

Hawkins KL, Montague BT, Rowan SE, Beum R, McLees MP, Johnson S, Gardner EM. Hawkins KL, et al. Antivir Ther. 2019;24(7):513-519. doi: 10.3851/IMP3330. Antivir Ther. 2019. PMID: 31538963

134

Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.

Grasso AG, Sonzogni A, Zanon D, Maestro A, Loiacono S, Maximova N. Grasso AG, et al. Antivir Ther. 2019;24(8):603-607. doi: 10.3851/IMP3332. Antivir Ther. 2019. PMID: 31509110

135

Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.

Vannappagari V, Ragone L, Henegar C, van Wyk J, Brown D, Demarest J, Quercia R, St Clair M, Underwood M, Gatell JM, de Ruiter A, Aboud M. Vannappagari V, et al. Antivir Ther. 2019;24(6):393-404. doi: 10.3851/IMP3331. Antivir Ther. 2019. PMID: 31503008

136

Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.

Boglione L, De Nicolò A, Di Perri G, D'Avolio A. Boglione L, et al. Antivir Ther. 2019;24(7):553-555. doi: 10.3851/IMP3328. Antivir Ther. 2019. PMID: 31502554 No abstract available.

137

No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.

Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, Reitmann C, Guo Y, Liu R, Iwamoto M. Anderson MS, et al. Antivir Ther. 2019;24(6):443-450. doi: 10.3851/IMP3324. Antivir Ther. 2019. PMID: 31433304 Clinical Trial.

138

Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.

Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C. Balmaceda JB, et al. Antivir Ther. 2019;24(4):451-457. doi: 10.3851/IMP3327. Antivir Ther. 2019. PMID: 31359874 Free PMC article.

139

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.

Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H. Gatell JM, et al. Antivir Ther. 2019;24(6):425-435. doi: 10.3851/IMP3323. Antivir Ther. 2019. PMID: 31355775 Clinical Trial.

140

Retraction: Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.

Skarnovich MA, Emelyanova AG, Petrova NV, Borshcheva AA, Gorbunov EA, Mazurkov OY, Skarnovich MO, Tarasov SA, Shishkina LN, Epstein OI. Skarnovich MA, et al. Antivir Ther. 2019;24(3):235. doi: 10.3851/IMP3325. Antivir Ther. 2019. PMID: 31348765 No abstract available.

141

Antiviral drug utilization and annual expenditures for patients with chronic HBV infection in Guangzhou, China, in 2008-2015.

Zhou F, Jia W, Yang S, Chen G, Li G, Li Y, Liang Y, Yang Y, Gao Y, Chen Y. Zhou F, et al. Antivir Ther. 2019;24(6):405-416. doi: 10.3851/IMP3326. Antivir Ther. 2019. PMID: 31348006

142

miRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon-free antiviral therapy.

Peveling-Oberhag J, Bankov K, Dultz G, Ballo O, Lohmeyer J, Brunnberg U, Marcu V, Walter D, Zeuzem S, Hansmann ML, Welzel TM, Vermehren J. Peveling-Oberhag J, et al. Antivir Ther. 2019;24(6):437-442. doi: 10.3851/IMP3322. Antivir Ther. 2019. PMID: 31180334

143

Use of oseltamivir in lung transplant recipients with suspected or proven influenza infection: a 1-year observational study of outcomes and safety.

Jungo C, Russmann S, Benden C, Schuurmans MM. Jungo C, et al. Antivir Ther. 2019;24(7):495-503. doi: 10.3851/IMP3320. Antivir Ther. 2019. PMID: 31172978

144

Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.

Vizcarra P, Fontecha M, Monsalvo M, Vivancos MJ, Rojo A, Casado JL. Vizcarra P, et al. Antivir Ther. 2019;24(6):467-471. doi: 10.3851/IMP3319. Antivir Ther. 2019. PMID: 31172977

145

Generic substitution of antiretroviral agents: never a problem?

Burger D, Oosterhof P. Burger D, et al. Antivir Ther. 2019;24(6):389-391. doi: 10.3851/IMP3321. Antivir Ther. 2019. PMID: 31172976 No abstract available.

146

Performance assessment of a fully automated deep sequencing platform for HCV resistance testing.

Rodriguez C, Mercier-Darty M, Soulier A, Poiteau L, Wlassow M, Fourati S, Hézode C, Pawlotsky JM, Chevaliez S. Rodriguez C, et al. Antivir Ther. 2019;24(6):417-423. doi: 10.3851/IMP3318. Antivir Ther. 2019. PMID: 31112134

147

Vitamin D does not modulate immune-mediated bone loss during ART initiation.

Yin MT, Chan ES, Brown TT, Kinslow J, Martinson J, Landay A, Melbourne KM, Ribaudo HJ, Overton ET; A5280 Study Team. Yin MT, et al. Antivir Ther. 2019;24(5):355-362. doi: 10.3851/IMP3316. Antivir Ther. 2019. PMID: 31085814 Free PMC article.

148

Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales.

Ong AT, Tay E, Dwyer DE, George J, Douglas MW. Ong AT, et al. Antivir Ther. 2019;24(4):281-290. doi: 10.3851/IMP3317. Antivir Ther. 2019. PMID: 31085813

149

Acute renal failure related to high doses of acyclovir (15 mg/kg/8 h) during treatment of varicella zoster virus encephalitis.

Martinot M, Klein A, Demesmay K, Groza M, Mohseni-Zadeh M, Tebacher-Alt M, Fafi-Kremer S. Martinot M, et al. Antivir Ther. 2019;24(4):309-312. doi: 10.3851/IMP3313. Antivir Ther. 2019. PMID: 31081790

150

Correction: Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.

Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, Li Q, Liu L, Wang J, Huang B, Lu F, Xu D. Liao H, et al. Antivir Ther. 2019;24(2):151. doi: 10.3851/IMP3314. Antivir Ther. 2019. PMID: 31050658 No abstract available.

151

Lean mass declines consistently over 10 years in people living with HIV on antiretroviral therapy, with patterns differing by sex.

Debroy P, Lake JE, Sim M, Erlandson KM, Falutz J, Prado CM, Brown TT, Guaraldi G, Metabolic Cohort Team TMH. Debroy P, et al. Antivir Ther. 2019;24(5):383-387. doi: 10.3851/IMP3312. Antivir Ther. 2019. PMID: 31032811 Free PMC article.

152

Reaching 90-90-90: outcomes of a 15-year multi-country HIV workplace programme in sub-Saharan Africa.

Boerma R, Schellekens O, Rinke de Wit TF, Wit FW, van der Borght S, Rijckborst H, Chukwumah P, Schilthuis H. Boerma R, et al. Antivir Ther. 2019;24(5):363-370. doi: 10.3851/IMP3311. Antivir Ther. 2019. PMID: 31017125

153

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

Young J, Scherrer AU, Calmy A, Tarr PE, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard HF, Bucher HC; Swiss HIV Cohort Study. Young J, et al. Antivir Ther. 2019;24(5):343-353. doi: 10.3851/IMP3310. Antivir Ther. 2019. PMID: 30985290

154

Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia.

Hudson FP, Mulenga L, Westfall AO, Warrier R, Mweemba A, Saag MS, Stringer JS, Eron JJ, Chi BH. Hudson FP, et al. Antivir Ther. 2019;24(4):291-300. doi: 10.3851/IMP3299. Antivir Ther. 2019. PMID: 30977467 Free PMC article.

155

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.

Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Armenia D, et al. Antivir Ther. 2019;24(5):321-331. doi: 10.3851/IMP3309. Antivir Ther. 2019. PMID: 30977466 Free article.

156

Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant.

Zondagh J, Basson AE, Achilonu I, Morris L, Dirr HW, Sayed Y. Zondagh J, et al. Antivir Ther. 2019;24(5):333-342. doi: 10.3851/IMP3308. Antivir Ther. 2019. PMID: 30958309

157

Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients.

Yuste JR, López-Díaz de Cerio A, Rifón J, Moreno C, Panizo M, Inogés S. Yuste JR, et al. Antivir Ther. 2019;24(4):313-319. doi: 10.3851/IMP3307. Antivir Ther. 2019. PMID: 30912764

158

Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.

Ford SL, Lou Y, Lewis N, Kostapanos M, D'Amico R, Spreen W, Patel P. Ford SL, et al. Antivir Ther. 2019;24(4):301-308. doi: 10.3851/IMP3306. Antivir Ther. 2019. PMID: 30896438 Clinical Trial.

159

Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment.

Liu Y, Wu C, Chen R, Li X, Xu Z, Li Q, Li L, Wang FS, Yang D, Lu M, Xu D. Liu Y, et al. Antivir Ther. 2019;24(4):237-246. doi: 10.3851/IMP3305. Antivir Ther. 2019. PMID: 30882363

160

Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle.

Park SB, Boyer A, Hu Z, Le D, Liang TJ. Park SB, et al. Antivir Ther. 2019;24(5):371-381. doi: 10.3851/IMP3303. Antivir Ther. 2019. PMID: 30880685

161

High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.

Gozlan Y, Bucris E, Shirazi R, Rakovsky A, Ben-Ari Z, Davidov Y, Veizman E, Saadi T, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Katchman H, Menachem Y, Safadi R, Galun E, Zuckerman E, Nimer A, Hazzan R, Maor Y, Saif AM, Etzion O, Lurie Y, Mendelson E, Mor O. Gozlan Y, et al. Antivir Ther. 2019;24(3):221-228. doi: 10.3851/IMP3301. Antivir Ther. 2019. PMID: 30880684

162

Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP.

Younger J, Raboud J, Szadkowski L, Harrigan R, Walmsley S, Bayoumi AM, Klein MB, Cooper C, Burchell AN, Loutfy M, Hull M, Wong A, Thomas R, Hogg R, Montaner J, Tsoukas C, Antoniou T; Canadian Observational Cohort Collaboration. Younger J, et al. Antivir Ther. 2019;24(3):211-220. doi: 10.3851/IMP3302. Antivir Ther. 2019. PMID: 30873953

163

Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.

Pavlovic V, Yang L, Chan HL, Hou J, Janssen HL, Kao JH, Lampertico P, Peng CY, Piratvisuth T, Thompson AJ, Wedemeyer H, Wei L, Wat C. Pavlovic V, et al. Antivir Ther. 2019;24(2):133-140. doi: 10.3851/IMP3304. Antivir Ther. 2019. PMID: 30865588

164

The impact of a successful treatment of HCV on glyco-metabolic control in diabetic patients.

Carnovale C, Gentili M, Magni C, Mazhar F, Mosini G, Clementi E, Radice S. Carnovale C, et al. Antivir Ther. 2019;24(2):147-149. doi: 10.3851/IMP3300. Antivir Ther. 2019. PMID: 30835253 Free article. No abstract available.

165

Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD).

Bijker R, Kumarasamy N, Kiertiburanakul S, Pujari S, Lam W, Chaiwarith R, Wong WW, Kamarulzaman A, Kantipong P, Avihingsanon A, Nguyen KV, Tanuma J, Ng OT, Sim BL, Merati TP, Choi JY, Ditangco R, Yunihastuti E, Sun LP, Do CD, Ross J, Law M; TREAT Asia HIV Observational Database (TAHOD) of IeDEA Asia-Pacific. Bijker R, et al. Antivir Ther. 2019;24(4):271-279. doi: 10.3851/IMP3298. Antivir Ther. 2019. PMID: 30833516 Free PMC article.

166

HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis.

Wang J, Hu C, Chen Y, Liu Z, Yu Q, Yang S, Dong J, Yang Y, Wu Y, Ren D, Yao N, Guo D, Tian Z, Zhao Y, Chen T, He Y, Liu J. Wang J, et al. Antivir Ther. 2019;24(2):77-84. doi: 10.3851/IMP3292. Antivir Ther. 2019. PMID: 30833515

167

Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment.

Pisaturo M, Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Claar E, Precone D, Stornaiuolo G, Stanzione M, Gentile I, Brancaccio G, Martini S, Masiello A, Megna AS, Coppola C, Federico A, Sagnelli E, Persico M, Lanza AG, Marrone A, Gaeta GB, Coppola N. Pisaturo M, et al. Antivir Ther. 2019;24(7):485-493. doi: 10.3851/IMP3296. Antivir Ther. 2019. PMID: 30758299

168

Inhibitory effect of iota-carrageenan on porcine reproductive and respiratory syndrome virus in vitro.

Guo C, Zhu Z, Yu P, Zhang X, Dong W, Wang X, Chen Y, Liu X. Guo C, et al. Antivir Ther. 2019;24(4):261-270. doi: 10.3851/IMP3295. Antivir Ther. 2019. PMID: 30747721

169

Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.

Jarrin I, Suarez-Garcia I, Moreno C, Tasias M, Del Romero J, Palacios R, Peraire J, Gorgolas M, Moreno S; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Jarrin I, et al. Antivir Ther. 2019;24(3):167-175. doi: 10.3851/IMP3297. Antivir Ther. 2019. PMID: 30747107

170

Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods.

Hunt GM, Ledwaba J, Kalimashe M, Salimo A, Cibane S, Singh B, Puren A, Dean NE, Morris L, Jordan MR. Hunt GM, et al. Antivir Ther. 2019;24(3):203-210. doi: 10.3851/IMP3294. Antivir Ther. 2019. PMID: 30741163

171

Therapeutic drug monitoring of darunavir/ritonavir in pregnancy.

Murtagh R, Else LJ, Kuan KB, Khoo SH, Jackson V, Patel A, Lawler M, McDonald G, Le Blanc D, Avramovic G, Redmond N, Lambert JS. Murtagh R, et al. Antivir Ther. 2019;24(3):229-233. doi: 10.3851/IMP3291. Antivir Ther. 2019. PMID: 30728322

172

Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.

Halloran MO, Boyle C, Kehoe B, Bagkeris E, Mallon P, Post FA, Vera J, Williams I, Anderson J, Winston A, Sachikonye M, Sabin C, Boffito M. Halloran MO, et al. Antivir Ther. 2019;24(3):193-201. doi: 10.3851/IMP3293. Antivir Ther. 2019. PMID: 30700636

173

Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature review.

Szilberhorn L, Kaló Z, Ágh T. Szilberhorn L, et al. Antivir Ther. 2019;24(4):247-259. doi: 10.3851/IMP3290. Antivir Ther. 2019. PMID: 30652971

174

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K. Tatsukawa Y, et al. Antivir Ther. 2019;23(8):709. doi: 10.3851/IMP3289. Antivir Ther. 2019. PMID: 30632982 No abstract available.

175

Behaviour of occult HBV infection in HCV-infected patients under treatment with direct-acting antivirals.

Musolino C, Cacciola I, Tripodi G, Lombardo D, Raffa G, Alibrandi A, Squadrito G, Raimondo G, Pollicino T. Musolino C, et al. Antivir Ther. 2019;24(3):187-192. doi: 10.3851/IMP3288. Antivir Ther. 2019. PMID: 30628893

176

Impact of three decades of antiretroviral therapy in a longitudinal population cohort study.

Hanhoff N, Vu Q, Lang R, Gill MJ. Hanhoff N, et al. Antivir Ther. 2019;24(3):153-165. doi: 10.3851/IMP3287. Antivir Ther. 2019. PMID: 30614788

177

Frailty as a predictor of falls in HIV-infected and uninfected women.

Sharma A, Hoover DR, Shi Q, Gustafson DR, Plankey MW, Tien PC, Weber KM, Yin MT. Sharma A, et al. Antivir Ther. 2019;24(1):51-61. doi: 10.3851/IMP3286. Antivir Ther. 2019. PMID: 30604692 Free PMC article.

178

Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients.

Medina-Moreno S, Zapata JC, Cottrell ML, Le NM, Tao S, Bryant J, Sausville E, Schinazi RF, Kashuba AD, Redfield RR, Heredia A. Medina-Moreno S, et al. Antivir Ther. 2019;24(3):177-186. doi: 10.3851/IMP3285. Antivir Ther. 2019. PMID: 30574873 Free PMC article.

179

Tenofovir plus hepatitis B immunoglobulin treatment resulted in a rapid HBV DNA load decline in high-risk pregnant women who missed the optimal time window of antiviral prophylaxis.

Chen T, Liu J, Yu Q, Yao N, Yang Y, Wu Y, Ren D, Tian Z, Zhao Y, Wang J. Chen T, et al. Antivir Ther. 2019;24(2):125-131. doi: 10.3851/IMP3284. Antivir Ther. 2019. PMID: 30570488

180

Efavirenz pharmacokinetics during pregnancy and infant washout.

Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, Shapiro D, Cressey T, Mirochnick M, Burger D. Kreitchmann R, et al. Antivir Ther. 2019;24(2):95-103. doi: 10.3851/IMP3283. Antivir Ther. 2019. PMID: 30530925 Free PMC article.

181

Association of serum total cholesterol with pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients.

Xun Z, Lin JP, Liu C, Huang JL, Shen Y, Xu SY, Wu WN, Ou QS. Xun Z, et al. Antivir Ther. 2019;24(2):85-93. doi: 10.3851/IMP3282. Antivir Ther. 2019. PMID: 30520414

182

Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.

Bremer B, Anastasiou OE, Ciesek S, Wedemeyer H. Bremer B, et al. Antivir Ther. 2019;24(2):117-123. doi: 10.3851/IMP3281. Antivir Ther. 2019. PMID: 30516520

183

Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.

Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, Li Q, Liu L, Wang J, Huang B, Lu F, Xu D. Liao H, et al. Antivir Ther. 2019;24(2):105-115. doi: 10.3851/IMP3280. Antivir Ther. 2019. PMID: 30511941

184

HSV susceptibility to acyclovir - genotypic and phenotypic characterization.

Vikas R, Prabhu SG, Mudgal PP, Shetty U, Karunakaran K, Jagadesh A, Auti A, Stansilaus RP, Nair S, Arunkumar G. Vikas R, et al. Antivir Ther. 2019;24(2):141-145. doi: 10.3851/IMP3279. Antivir Ther. 2019. PMID: 30507553

185

Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).

Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F, Ramji A, Shafran SD, McPhee F, Yang R, Noviello S, Linaberry M; ALLY-3C study team. Poordad F, et al. Antivir Ther. 2019;24(1):35-44. doi: 10.3851/IMP3278. Antivir Ther. 2019. PMID: 30382942

186

Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.

Dumond JB, Greene SA, Prince HMA, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JAE, Gay CL, Kashuba ADM, Cohen MS. Dumond JB, et al. Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277. Antivir Ther. 2019. PMID: 30375984 Free PMC article.

187

Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.

Denault JS, Cabot JF, Langlois H, Marcotte S, Sheehan NL. Denault JS, et al. Antivir Ther. 2019;24(1):73-76. doi: 10.3851/IMP3274. Antivir Ther. 2019. PMID: 30353885

188

Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients.

Ferrari D, Spagnuolo V, Manca M, Bigoloni A, Muccini C, Banfi G, Locatelli M, Castagna A. Ferrari D, et al. Antivir Ther. 2019;24(1):69-72. doi: 10.3851/IMP3275. Antivir Ther. 2019. PMID: 30353884

189

A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.

Ciccullo A, Baldin G, Capetti A, Rusconi S, Sterrantino G, d'Ettorre G, Colafigli M, Modica S, Lagi F, Giacomelli A, Cossu MV, Restelli S, De Luca A, Di Giambenedetto S. Ciccullo A, et al. Antivir Ther. 2019;24(1):63-67. doi: 10.3851/IMP3270. Antivir Ther. 2019. PMID: 30277466

190

Autophagy involved in antiviral activity of sodium tanshinone IIA sulfonate against porcine reproductive and respiratory syndrome virus infection in vitro.

Sun N, Sun P, Yao M, Khan A, Sun Y, Fan K, Yin W, Li H. Sun N, et al. Antivir Ther. 2019;24(1):27-33. doi: 10.3851/IMP3268. Antivir Ther. 2019. PMID: 30272564

191

Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.

Ladak F, Socias E, Nolan S, Dong H, Kerr T, Wood E, Montaner J, Milloy MJ. Ladak F, et al. Antivir Ther. 2019;24(1):19-25. doi: 10.3851/IMP3265. Antivir Ther. 2019. PMID: 30230474 Free PMC article.

192

Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.

Mathur P, Kottilil S, Wilson E. Mathur P, et al. Antivir Ther. 2019;24(1):1-10. doi: 10.3851/IMP3264. Antivir Ther. 2019. PMID: 30210057 Review.

193

Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.

Vega AD, Hynicka LM, Claeys K, Chua JV, Heil EL. Vega AD, et al. Antivir Ther. 2019;24(1):11-17. doi: 10.3851/IMP3263. Antivir Ther. 2019. PMID: 30192231

194

Correction: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance.

Abdurakhmanov DT, Rozina TP, Nikulkina EN, Nabatchikova EA, Chulanov VP, Moiseev SV. Abdurakhmanov DT, et al. Antivir Ther. 2018;23(8):713. doi: 10.3851/IMP3273. Antivir Ther. 2018. PMID: 30681414 No abstract available.

195

Hindsight is 20/20 - the importance of knowing! Know your patients' HBV status.

Sanaka S, Tillmann HL. Sanaka S, et al. Antivir Ther. 2018;23(6):471-473. doi: 10.3851/IMP3260. Antivir Ther. 2018. PMID: 30538213 No abstract available.

196

Expert opinion on managing chronic HCV infection in patients with type 2 diabetes mellitus.

Adinolfi LE, Jacobson I, Bondin M, Cacoub P. Adinolfi LE, et al. Antivir Ther. 2018;23(Suppl 2):11-21. doi: 10.3851/IMP3255. Antivir Ther. 2018. PMID: 30451154 Free article. Review.

197

Expert opinion on the management of renal manifestations of chronic HCV infection.

Fabrizi F, Negro F, Bondin M, Cacoub P. Fabrizi F, et al. Antivir Ther. 2018;23(Suppl 2):57-67. doi: 10.3851/IMP3247. Antivir Ther. 2018. PMID: 30451153 Free article. Review.

198

Expert opinion on managing chronic HCV in patients with cardiovascular disease.

Vassalle C, Petta S, Pepe A, Craxi A, Bondin M, Cacoub P. Vassalle C, et al. Antivir Ther. 2018;23(Suppl 2):35-46. doi: 10.3851/IMP3248. Antivir Ther. 2018. PMID: 30451152 Free article. Review.

199

Expert opinion on managing chronic HCV in patients with mixed cryoglobulinaemia vasculitis.

Zignego AL, Pawlotsky JM, Bondin M, Cacoub P. Zignego AL, et al. Antivir Ther. 2018;23(Suppl 2):1-9. doi: 10.3851/IMP3246. Antivir Ther. 2018. PMID: 30451151 Free article. Review.

200

Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

Forton D, Weissenborn K, Bondin M, Cacoub P. Forton D, et al. Antivir Ther. 2018;23(Suppl 2):47-55. doi: 10.3851/IMP3245. Antivir Ther. 2018. PMID: 30451150 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

2,482 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

2,482 results

Results by year